Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04928508 · ClinicalTrials.gov registry record · Phase 1

Advanced or Recurrent Solid Tumors Treated With SHetA2

A Phase 1 study of Solid Tumor, Adult, sponsored by University of Oklahoma.

Recruiting
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT04928508 is a Phase 1 study of Solid Tumor, Adult that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 50 participants, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04928508, a Phase 1 study of Solid Tumor, Adult, is actively recruiting participants, sponsored by University of Oklahoma.

RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to test the safety of the study drug (OK-1) and see what effects (good and bad) this drug has on patients with recurrent solid tumors.

Conditions Studied

Solid Tumor, Adult

Interventions

  • DRUG OK-1

Study Locations (1)

Oklahoma

  • Stephenson Cancer Center - Oklahoma City

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-07-27
Est. Completion 2027-06
Phase Phase 1

Sponsor

University of Oklahoma

358 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04928508

The ClinicalTrials.gov registry entry for NCT04928508 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (74% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which OK-1 is the first listed.

NCT04928508 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT04928508 about?

NCT04928508 is a clinical study titled "Advanced or Recurrent Solid Tumors Treated With SHetA2". The purpose of this research is to test the safety of the study drug (OK-1) and see what effects (good and bad) this drug has on patients with recurrent solid tumors.

What is the current status of trial NCT04928508?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2022-07-27. Estimated completion is 2027-06.

What conditions does trial NCT04928508 study?

This clinical trial studies the following conditions: Solid Tumor, Adult.

What interventions are being tested in trial NCT04928508?

The interventions under investigation include: OK-1 (DRUG).

Who is sponsoring clinical trial NCT04928508?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04928508 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor, Adult

All registered trials for this condition

Oklahoma

All trials with a study site in Oklahoma

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.